HealthTree Logo
search more_vert
person Sign In / Create Account
Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester
Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester image
HealthTree Podcast for AML
event Jun 29, 2022 / 02:00PM EDT

Event Description


*You need to join by phone if you want to ask Dr. Liesveld your questions.

The FLT3 gene mutation is the most common mutation seen in acute myeloid leukemia patients. It occurs in approximately 30% of adult patients with AML. FLT3 mutations have been harder to treat with poor outcomes, however, with combination therapies using targeted drugs such as FLT3 inhibitors, outcomes have greatly improved. The development of FLT3 inhibitors has progressed in recent years and there are currently two FDA-approved options - gilteritinib and midostaurin. There are also many additional FLT3 inhibitors in development such as crenolanib and quizartinib, which leads us to the question of which FLT3 inhibitor should be used for each person and when is the appropriate time to add it to treatment?

Join us live on June 29th at 2 PM EST to hear from Dr. Jane Liesveld from the University of Rochester who will discuss the different FLT3 inhibitor options currently available, as well as the ones in development. Dr. Liesveld will also share research with us from a clinical trial she is leading comparing midostaurin and crenolanib when given following induction and consolidation in newly diagnosed FLT3 positive patients.

During the show, Dr. Liesveld will discuss the differences between FLT3 inhibitor options and what has been learned from previous FLT3 inhibitor trials. Come learn all about the FLT3 mutation, FLT3 inhibitors and have the opportunity to directly ask Dr. Liesveld your questions.

Thank you to our episode sponsor, Abbvie.

Schedule & Agenda

Kerith Amen
Welcome, Announcements and Introduction
Dr. Jane Liesveld, MD
Dr. Liesveld will discuss the different FLT3 inhibitor options, what has been learned from previous trials with FLT3 inhibitors and a current trial comparing midostaurin and crenolanib.
Audience is able to call in to the radio show, (515) 602-9728, to ask Dr. Liesveld questions about what was discussed during our interview today.

Speakers & Moderators

The panelist Kerith Amen
Kerith Amen
New Orleans, Louisiana

Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.

Read Bio
The panelist Jane Liesveld, MD
Jane Liesveld, MD
Rochester, NY

Professor of Medicine in the Division of Hematology and Oncology and Clinical Director of the Blood and Marrow Transplantation Program at the University of Rochester School of Medicine and Dentistry

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us




Get the latest thought leadership on Acute Myeloid Leukemia delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Acute Myeloid Leukemia Newsletter" for Acute Myeloid Leukemia news, life with Acute Myeloid Leukemia stories, Acute Myeloid Leukemia clinical trials, Acute Myeloid Leukemia 101 articles and events with Acute Myeloid Leukemia experts.

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Astellas Pharma

Follow Us

facebook instagram youtube